Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Oct;97(43):e12978.
doi: 10.1097/MD.0000000000012978.

Choosing between ticagrelor and clopidogrel following percutaneous coronary intervention: A systematic review and Meta-Analysis (2007-2017)

Wenjun Guan  1 , Hongtao Lu, Keping Yang
Affiliations
Free PMC article
Review

Choosing between ticagrelor and clopidogrel following percutaneous coronary intervention: A systematic review and Meta-Analysis (2007-2017)

Wenjun Guan et al. Medicine (Baltimore). 2018 Oct.
Free PMC article

Abstract

Background: Limitations have been observed with the use of clopidogrel following percutaneous coronary intervention (PCI) indicating the urgent need of a more potent anti-platelet agent. We aimed to compare the efficacy and safety of ticagrelor versus clopidogrel following PCI.

Methods: Online databases were searched for relevant studies (published between the years 2007 and 2017) comparing ticagrelor versus clopidogrel following coronary stenting. Primary outcomes assessed efficacy whereas secondary outcomes assessed safety. Odds ratios (OR) with 95% confidence intervals (CIs) based on a random effect model were calculated and the analysis was carried out by the RevMan 5.3 software.

Results: A total number of 25,632 patients with acute coronary syndrome (ACS) [12,992 patients with ST segment elevation myocardial infarction (STEMI) and 14,215 patients with non-ST segment elevation myocardial infarction (NSTEMI)] were included in this analysis, of whom 23,714 patients were revascularized by PCI. Results of this analysis did not show any significant difference in all-cause mortality, major adverse cardiac events (MACEs), myocardial infarction, stroke and stent thrombosis observed between ticagrelor and clopidogrel with (OR: 0.83, 95% CI: 0.67-1.03; P = .09), (OR: 0.64, 95% CI: 0.41-1.01; P = .06), (OR: 0.77, 95% CI: 0.57-1.03; P = .08), (OR: 0.85, 95% CI: 0.57-1.26; P = .42) and (OR: 0.70, 95% CI: 0.47-1.05; P =.09).However, ticagrelor was associated with a significantly higher minor and major bleeding with (OR: 1.57, 95% CI: 1.30-1.89; P = .00001) and (OR: 1.52, 95% CI: 1.01-2.29; P = 0.04) respectively. Dyspnea was also significantly higher in the ticagrelor group (OR: 2.64, 95% CI: 1.87-3.72; P = .00001).

Conclusion: Ticagrelor and clopidogrel were comparable in terms of efficacy in these patients with ACS. However, the safety outcomes of ticagrelor should further be investigated.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to disclose.

Figures

Figure 1
Figure 1
Flow diagram representing the study selection for this analysis.
Figure 2
Figure 2
Comparing the efficacy (primary outcomes) observed between Ticagrelor and Clopidogrel.
Figure 3
Figure 3
Comparing the bleeding events (secondary outcomes) observed between Ticagrelor and Clopidogrel.
Figure 4
Figure 4
Comparing the adverse drug events (secondary outcomes) observed between Ticagrelor and Clopidogrel.
Figure 5
Figure 5
Funnel plot showing publication bias (A).
Figure 6
Figure 6
Funnel plot showing publication bias (B).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Emmanouil S, Brilakis, Vishal G, et al. Medical management after coronary stent implantation: a review. JAMA 2013;310:189–98. - PubMed
    1. Galper BZ, Mauri L. Antiplatelet therapy after coronary stenting. Curr Treat Options Cardiovasc Med 2013;15:1–0. - PubMed
    1. Zhuo X, Zhuo B, Ouyang S, et al. Adverse clinical outcomes associated with double dose clopidogrel compared to the other antiplatelet regimens in patients with coronary artery disease: a systematic review and meta-analysis. BMC Pharmacol Toxicol 2018;19:54. - PMC - PubMed
    1. Bundhun PK, Teeluck AR, Bhurtu A, et al. Is the concomitant use of clopidogrel and Proton Pump Inhibitors still associated with increased adverse cardiovascular outcomes following coronary angioplasty?: a systematic review and meta-analysis of recently published studies (2012–2016). BMC Cardiovasc Disord 2017;17:3. - PMC - PubMed
    1. Kang HJ, Clare AM, Gao R, et al. PLATO investigators. ticagrelor versus clopidogrel in Asian patients with acute coronary syndrome: A retrospective analysis from the platelet inhibition and patient outcomes (PLATO) trial. Am Heart J 2015;169:899–905. - PubMed

MeSH terms